EUVIMEDEUVIMED entdecken
Crossref

High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib

Luke Quinlan, Elyse C Page, Jacqueline Rehn, Barbara J McClure iD, Michael P Osborn iD, Andrew S Moore iD, Rishi S Kotecha iD, Michelle J Henderson, Michelle Martin, Frank Alvaro, David T Yeung, Deborah L White und 1 weitere

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31983 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Luke Quinlan und 12 weiteren Autor:innen. Beteiligte Einrichtung: South Australian Health and Medical Research Institute (SAHMRI), Blood Cancer Program, Precision Cancer Medicine Theme, Adelaide, South Australia, Au…. Hauptthemen laut MEDLINE: Receptor, trkA, Core Binding Factor Alpha 2 Subunit, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Pyrazoles. Die Arbeit nennt 32 Literaturangaben. Gefördert von: National Health and Medical Research Council, Medical Research Future Fund, Australia, Channel 7 Children's Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ETV6 :: RUNX1 is one of the most common recurrent genomic abnormalities in acute lymphoblastic leukaemia (ALL) and is associated with a good prognosis. High expression of NTRK1 , encoding tropomyosin receptor kinase A (TrkA), confers a poor prognosis in other malignancies and may contribute to therapy resistance in patients with ETV6::RUNX1 B‐ALL.

Method

Relapse‐free survival was estimated by the Kaplan–Meier and log‐rank analyses. ETV6::RUNX1 and NTRK1 were isolated from patient cDNA and transduced into IL‐3–dependent Ba/F3 cells. Proliferation was assessed via CellTiter‐Glo‐2.0 with the addition of the TrkA agonist, nerve growth factor (NGF). Sensitivity to the TRK inhibitor larotrectinib was assessed via Annexin V/7AAD staining and flow cytometry. Changes in TrkA signalling through effectors, ERK and AKT, were evaluated by western blotting.

Results

Patients with ETV6::RUNX1 had increased NTRK1 expression in comparison with other B‐ALL cases ( p < 0.0001), with those overexpressing NTRK1 exhibiting a trend towards increased relapse. in vitro experiments revealed that only Ba/F3 ETV6::RUNX1 + NTRK1 cells demonstrated IL‐3 independence, indicative of leukaemic transformation (vs parental Ba/F3, p < 0.0001). These cells were sensitive to larotrectinib (LD 50 161 nM) and significantly decreased phosphorylation of ERK and AKT (vs NGF p = 0.0004; p = 0.007, respectively).

Conclusion

NTRK1 overexpression has not previously been reported in B‐ALL and was associated with increased relapse in patients with ETV6::RUNX1 and NTKR1 overexpression. The in vitro success of larotrectinib treatment warrants further in vivo investigation and may be a viable therapeutic addition for patients with ETV6::RUNX1 B‐ALL and NTRK1 overexpression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, trkACore Binding Factor Alpha 2 SubunitPrecursor Cell Lymphoblastic Leukemia-LymphomaPyrazolesPyrimidinesOncogene Proteins, FusionProto-Oncogene Proteins c-etsRepressor ProteinsDrug Resistance, NeoplasmHumansChildMaleFemaleETS Translocation Variant 6 ProteinChild, PreschoolPrognosisAdolescentTumor Cells, Cultured

Stichwörter der Autor:innen

ALLALL relapseCancer geneticsHematology/OncologyPediatric hematology/oncologymolecular diagnosis & therapy

Substanzen

Receptor, trkACore Binding Factor Alpha 2 SubunitNTRK1 protein, humanlarotrectinibPyrazolesPyrimidinesRUNX1 protein, humanOncogene Proteins, FusionETS Translocation Variant 6 ProteinProto-Oncogene Proteins c-ets

Autor:innen und Institutionen

  • South Australian Health and Medical Research Institute (SAHMRI), Blood Cancer Program, Precision Cancer Medicine Theme, Adelaide, South Australia, Australia.
  • Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
  • Women's and Children's Hospital, Adelaide, South Australia, Australia.
  • Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG), Clayton, Victoria, Australia.
  • Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Oncology Service, Children's Health Queensland Hospital and Health Service, Brisbane, Queensland, Australia.

ORCID-Profile: Barbara J McClure, Michael P Osborn, Andrew S Moore, Rishi S Kotecha, Susan L Heatley

Förderung

  • National Health and Medical Research Council
  • Medical Research Future Fund, Australia
  • Channel 7 Children's Research Fund
  • Leukaemia Foundation, Australia
  • Cancer Council of South Australia
  • The Kid's Cancer Project

Zitieren

APA

Quinlan, L., Page, E. C., Rehn, J., McClure, B. J., Osborn, M. P., Moore, A. S., Kotecha, R. S., Henderson, M. J., Martin, M., Alvaro, F., Yeung, D. T., White, D. L., & Heatley, S. L. (2025). High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31983

Vancouver

Quinlan L, Page EC, Rehn J, McClure BJ, Osborn MP, Moore AS, et al. High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31983

BibTeX
@article{Quinlan2025,
  author = {Quinlan, Luke and Page, Elyse C and Rehn, Jacqueline and McClure, Barbara J and Osborn, Michael P and Moore, Andrew S and Kotecha, Rishi S and Henderson, Michelle J and Martin, Michelle and Alvaro, Frank and Yeung, David T and White, Deborah L and Heatley, Susan L},
  title = {High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31983}
}
Kostenlos starten →